What is the price of AIkido Pharma Inc. (AIKI)

The price of AIkido Pharma Inc. (AIKI) is $3.56

What is the market cap of AIkido Pharma Inc. (AIKI)

The market cap of AIkido Pharma Inc. (AIKI) is $18.70M

AIkido Pharma Inc. (AIKI) P/S Ratio

AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.

Year	P/S Ratio	Change
Not enough data for the provided dates.

Year

P/S Ratio

Change

Not enough data for the provided dates.

Company	P/S Ratio	P/S Ratio Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Company

P/S Ratio

P/S Ratio Difference

Country